Abstract
Aim: To investigate the overall survival of invasive breast cancer patients with primary breast conserving surgery (BCS) followed by re-excision compared to those with primary BCS only. The Dutch re-excision indications are less stringent compared to other European and Northern American countries (Society of Surgical Oncology-American Society for Radiation Oncology (SSO/ASTRO) guideline).
Methods: Retrospective analyses in women
Results: A total of 11,695 patients were included of which 2156 (18.4%) underwent re-excision. Median time of follow-up was 61 months (interquartile range (IQR) 26-101). The 5-year overall survival rates in the 'primary BCS only', 're-excision by BCS' and 're-excision by mastectomy' group were 92%, 95% and 91%, respectively. The 10-year overall survival rates were 81%, 82% and 79%, respectively (P = 0.20). After multivariable analyses no significant association was observed between use of and type of re-excision and overall survival.
Conclusions: The overall survival of breast cancer patients with a re-excision did not significantly differ from the survival of women who underwent primary BCS only. Advising re-excision only for those tumours showing 'more than focally positive' resection margin appears safe, supposing the long-term safety of the recent SSO/ASTRO guideline that more cautiously recommended re-excision for tumours showing 'ink on tumour'. (C) 2014 Elsevier Ltd. All rights reserved.
| Original language | English |
|---|---|
| Pages (from-to) | 282-291 |
| Number of pages | 10 |
| Journal | European Journal of Cancer |
| Volume | 51 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Feb 2015 |
Keywords
- Breast cancer
- Breast conserving surgery
- Re-excision
- Overall survival
- ONCOLOGY CONSENSUS GUIDELINE
- LOCAL RECURRENCE
- SURGICAL MARGINS
- CONSERVATION TREATMENT
- ADJUVANT CHEMOTHERAPY
- LUMPECTOMY MARGINS
- RANDOMIZED-TRIALS
- AMERICAN SOCIETY
- CANCER PATIENTS
- STAGES I